Navigation Links
AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
Date:3/7/2008

LARGO, Fla., March 7 /PRNewswire/ -- AlphaMed Pharmaceuticals Corporation announced today that the Company has successfully expressed a humanized version of the therapeutic protein alpha 1-antitrypsin (AAT). AlphaMed scientists expressed their recombinant AAT utilizing the Company's proprietary production system in yeast. The yeast has been genetically altered to produce a molecule "virtually identical" to that which is manufactured by the human body.

"This marks a major milestone for this company and AAT research," stated Joseph McGuirl, AlphaMed's CEO, "AlphaMed is the first company to develop an AAT molecule with glycosylation that resembles the human protein that is naturally secreted from the liver. The Company has begun to develop products to treat a variety of diseases including hereditary emphysema, COPD, asthma and cystic fibrosis." Joseph McGuirl joined AlphaMed in July, 2007 and is the former Head of Licensing and Development for Hoffmann-LaRoche.

"I am glad to confirm that the work progressed well so far," stated Dr. Roland Contreras Ph.D. of the VIB, University of Ghent located in Belgium who has been supervising AlphaMed's molecular biology. "The two complex sugars of the left arm have been added with good efficiency. This is an important milestone and in my opinion a glycoform worth purifying. It is a mammalian hybrid form."

Plasma-derived AAT is currently marketed by several companies for the treatment of hereditary emphysema and generates over $200 Million in revenues, annually. The plasma-derived AAT, however, is marked by shortages and blood contamination risks.

In addition, AAT plays a vital role in the inflammatory cascade and in many instances can act as a replacement for conventional steroids. Additional disease indications treatable by AAT therapy include atopic dermatitis, psoriasis, rheumatoid arthritis and others. "The market potential for AAT therapies is in the billions," stated McGuirl, "and given AlphaMed's intellectual property position this news represents a major leg up for the company".

AlphaMed is currently seeking developmental partners to continue its research for both topical and injectible/inhalable AAT therapies. The Company has successfully completed its second round of financing and has initiated a third round to complete Phase I clinical trials and initiate Phase II clinicals.

AlphaMed Pharmaceuticals Corporation is a privately held biopharmaceutical company located in Largo, Florida. Incorporated in 1999, the Company is dedicated to the successful development of both pharmaceutical and over-the counter products for human and animal use. AlphaMed's product pipeline includes AAT for pulmonary and dermatological use as well as cromolyn sodium for a variety of topical indications. AlphaMed expects its first product to market in early 2009.


'/>"/>
SOURCE AlphaMed Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
4. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
5. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
6. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
7. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):